AUTL

Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years after infusionSingle-cell analysis of…

At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months post-dosing at the highest dose…

<!-- Name:DistributionId Value:8838133 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

<!-- Name:DistributionId Value:8826366 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia therapy  Obe-cel: continues to show high level…

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia- obe-cel: poster presentation in r/r primary…

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the U.S. Food and Drug…

LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced publication of the obecabtagene…

Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade Cytokine Release Syndrome observed…